{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T11:16:14Z","timestamp":1760267774609,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejso.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Surgical Oncology"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.ejso.2021.04.039","type":"journal-article","created":{"date-parts":[[2021,5,3]],"date-time":"2021-05-03T12:57:25Z","timestamp":1620046645000},"page":"1920-1927","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["Correlation between outcome and extent of residual disease in the sentinel node after neoadjuvant chemotherapy in clinically fine-needle proven node-positive breast cancer patients"],"prefix":"10.1016","volume":"47","author":[{"given":"Giuseppe","family":"Canavese","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Corrado","family":"Tinterri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Franca","family":"Carli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elsa","family":"Garrone","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefano","family":"Spinaci","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Angelica","family":"Della Valle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Erika","family":"Barbieri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emilia","family":"Marrazzo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Paolo","family":"Bruzzi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Beatrice","family":"Dozin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejso.2021.04.039_bib1","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1200\/JCO.2016.71.0947","article-title":"Sentinel lymph node biopsy for patients with early-stage breast cancer: American society of clinical oncology clinical practice guideline update","volume":"35","author":"Lyman","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2021.04.039_bib2","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1097\/SLA.0b013e31812e6a73","article-title":"GIVOM trialists. A randomized clinical trial on sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer: results of the sentinella\/GIVOM trial","volume":"247","author":"Zavagno","year":"2008","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2021.04.039_bib3","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/S1470-2045(10)70207-2","article-title":"Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial","volume":"11","author":"Krag","year":"2010","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2021.04.039_bib4","doi-asserted-by":"crossref","unstructured":"VeronesiU, Viale G, Paganelli G, Zurrida S, Luini A, Galimberti V et\u00a0al, Sentinel lymph node biopsy in breast cancer: ten-year results of a randomized controlled study. AnnSurg2010; 51: 595-600.","DOI":"10.1097\/SLA.0b013e3181c0e92a"},{"key":"10.1016\/j.ejso.2021.04.039_bib5","doi-asserted-by":"crossref","first-page":"2494","DOI":"10.1245\/s10434-016-5177-4","article-title":"Sentinel lymph node biopsy versus axillary dissection in node-negative early-stage breast cancer: 15-year follow-up update of a randomized clinical trial","volume":"23","author":"Canavese","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2021.04.039_bib6","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1093\/jnci\/djj158","article-title":"Randomized multicenter trial of sentinel node biopsy versus standard axillary treatment in operable breast cancer: the ALMANAC Trial","volume":"98","author":"Mansel","year":"2006","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ejso.2021.04.039_bib7","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1016\/j.ejso.2007.05.017","article-title":"Morbidity comparison of sentinel lymph node biopsy versus conventional axillary lymph node dissection for breast cancer patients: results of the sentinella-GIVOM Italian randomised clinical trial","volume":"34","author":"Del Bianco","year":"2008","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2021.04.039_bib8","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/S1470-2045(18)30380-2","article-title":"International Breast Cancer Study Group Trial 23-01. Axillary dissection versus no axillary dissection in patients with breast cancer and sentinel-node micrometastases (IBCSG 23-01): 10-year follow-up of a randomised, controlled phase 3 trial","volume":"19","author":"Galimberti","year":"2018","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2021.04.039_bib9","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1001\/jama.2011.90","article-title":"Axillary dissection vs no axillary dissection in women with invasive breast cancer and sentinel node metastasis: a randomized clinical trial","volume":"305","author":"Giuliano","year":"2011","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.ejso.2021.04.039_bib10","doi-asserted-by":"crossref","unstructured":"Giuliano AE, Ballman K, McCall L, Beitsch P, Whitworth PW, Blumencranz P et\u00a0al. Locoregional recurrence after sentinel lymph node dissection with or without axillary dissection in patients with sentinel lymph node metastases: long-term follow-up from the American college of surgeons oncology group (alliance) ACOSOG Z0011 randomized trial.Ann Surg 201; 264: 413-420.","DOI":"10.1097\/SLA.0000000000001863"},{"key":"10.1016\/j.ejso.2021.04.039_bib11","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1093\/jnci\/82.19.1539","article-title":"Primary chemotherapy to avoid mastectomy in tumors with diameters of three centimeters or more","volume":"82","author":"Bonadonna","year":"1990","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.ejso.2021.04.039_bib12","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1634\/theoncologist.8-6-521","article-title":"Update on locally advanced breast cancer","volume":"8","author":"Giordano","year":"2003","journal-title":"Oncol"},{"key":"10.1016\/j.ejso.2021.04.039_bib13","doi-asserted-by":"crossref","first-page":"4165","DOI":"10.1200\/JCO.2003.12.005","article-title":"The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27","volume":"15","author":"Bear","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2021.04.039_bib14","doi-asserted-by":"crossref","DOI":"10.1097\/SLA.0000000000000924","article-title":"Tumor biology correlates with rates of breast-conserving surgery and pathologic complete response after neoadjuvant chemotherapy for breast cancer: findings from the ACOSOG Z1071 (Alliance) Prospective Multicenter Clinical Trial","volume":"260","author":"Boughey","year":"2014","journal-title":"Ann Surg"},{"key":"10.1016\/j.ejso.2021.04.039_bib15","doi-asserted-by":"crossref","first-page":"3467","DOI":"10.1245\/s10434-016-5246-8","article-title":"How often does neoadjuvant chemotherapy avoid axillary dissection in patients with histologically confirmed nodal metastases? Results of a prospective study","volume":"23","author":"Mamtani","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2021.04.039_bib16","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1158\/1078-0432.CCR-06-1345","volume":"13","author":"Buzdar","year":"2007","journal-title":"Clin Canc Res"},{"key":"10.1016\/j.ejso.2021.04.039_bib17","doi-asserted-by":"crossref","first-page":"10","DOI":"10.2325\/jbcs.14.10","article-title":"Sentinel lymph node biopsy is feasible for breast cancer patients after neoadjuvant chemotherapy","volume":"14","author":"Kinoshita","year":"2007","journal-title":"Breast Cancer"},{"key":"10.1016\/j.ejso.2021.04.039_bib18","first-page":"1","article-title":"Feasibility and accuracy of sentinel lymph node biopsy in clinically node-positive breast cancer after neoadjuvant chemotherapy:a meta-analysis","volume":"9","author":"Fu","year":"2010","journal-title":"PloS One"},{"key":"10.1016\/j.ejso.2021.04.039_bib19","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.ejso.2009.10.015","article-title":"Axillary sentinel node biopsy after neoadjuvant chemotherapy","volume":"36","author":"Ozmen","year":"2010","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2021.04.039_bib20","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.ejso.2011.05.012","article-title":"Accuracy of sentinel lymph node biopsy after neo-adjuvant chemotherapy in patients with locally advanced breast cancer and clinically positive axillary nodes","volume":"37","author":"Canavese","year":"2011","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2021.04.039_bib21","doi-asserted-by":"crossref","first-page":"9304","DOI":"10.1200\/JCO.2005.02.5023","article-title":"Outcome after pathological complete eradication of cytologically proven breast cancer node metastases following primary chemotherapy","volume":"23","author":"Hennessy","year":"2005","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2021.04.039_bib22","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ejso.2021.04.039_bib23","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/annonc\/mdn746","article-title":"Sentinel node biopsy compared with complete axillary dissection for staging early breast cancer with clinically negative lymph nodes: results of a randomized trial","volume":"10","author":"Canavese","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejso.2021.04.039_bib24","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S1470-2045(07)70278-4","volume":"8","author":"Krag","year":"2007","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2021.04.039_bib25","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1016\/j.ejso.2015.07.020","article-title":"The diagnostic performance of sentinel lymph node biopsy in pathologically confirmed node positive breast cancer patients after neoadjuvant systemic therapy: a systemic review and meta-analysis","volume":"41","author":"van Nijnatten","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2021.04.039_bib26","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1016\/j.amjsurg.2016.07.018","article-title":"Is sentinel lymph node biopsy a viable alternative to complete axillary dissection following neoadjuvant chemotherapy in women with node-positive breast cancer at diagnosis ? An updated meta-analysis involving 3,398 patients","volume":"212","author":"El HageChehade","year":"2016","journal-title":"Am J Surg"},{"key":"10.1016\/j.ejso.2021.04.039_bib27","doi-asserted-by":"crossref","first-page":"1455","DOI":"10.1001\/jama.2013.278932","article-title":"Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer. The ACOSOG Z1071 (Alliance) clinical trial","volume":"310","author":"Boughey","year":"2013","journal-title":"J\u00a0Am Med Assoc"},{"key":"10.1016\/j.ejso.2021.04.039_bib28","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(13)70166-9","article-title":"Sentinel-lymph-node biopsy in patients with breast cancer before and after neoadjuvantchemotherapy (SENTINA): a prospective, multicenter cohort study","volume":"14","author":"Kuehn","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejso.2021.04.039_bib29","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1200\/JCO.2014.55.7827","article-title":"Sentinel node biopsy after neoadjuvant chemotherapy in biopsy-proven node-positive breast cancer: the SN FNAC study","volume":"3","author":"Boileau","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2021.04.039_bib30","unstructured":"National comprehensive cancer network NCCN guidelines, version 2, 2021 \u2013 [www.nccn.org])."},{"key":"10.1016\/j.ejso.2021.04.039_bib31","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1200\/JCO.2015.64.0094","article-title":"Improved axillary evaluation following neoadjuvant therapy for patients with node-positive breast cancer using selective evaluation of clipped nodes: implementation of targeted axillary dissection","volume":"34","author":"Caudle","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2021.04.039_bib32","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1002\/bjs.5209","article-title":"Meta-analysis of sentinel lymph node biopsy after preoperative chemotherapy in patients with breast cancer","volume":"93","author":"Xing","year":"2006","journal-title":"Br J Surg"},{"key":"10.1016\/j.ejso.2021.04.039_bib33","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.4143\/crt.2015.456","article-title":"Locoregional recurrence by tumor biology in breast cancer patients after preoperative chemotherapy and breast conservation treatment","volume":"48","author":"Jwa","year":"2016","journal-title":"Cancer Res Treat"},{"issue":"suppl 3","key":"10.1016\/j.ejso.2021.04.039_bib34","doi-asserted-by":"crossref","first-page":"S495","DOI":"10.1245\/s10434-015-4697-7","article-title":"The effect of molecular subtype and residual disease on locoregional recurrence in breast cancer patients treated with neoadjuvant chemotherapy and postmastectomy radiation","volume":"22","author":"Yang","year":"2015","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ejso.2021.04.039_bib35","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.ejso.2015.01.036","article-title":"High expression of post-treatment Ki-67 status is a risk factor for locoregional recurrence following breast-conserving surgery after neoadjuvant chemotherapy","volume":"41","author":"Yamazaki","year":"2015","journal-title":"Eur J Surg Oncol"},{"key":"10.1016\/j.ejso.2021.04.039_bib36","series-title":"Higher locoregional recurrence rate for triple-negative breast cancer following neoadjuvant chemotherapy, surgery and radiotherapy","first-page":"386","volume":"4","author":"Zhang","year":"2015"},{"key":"10.1016\/j.ejso.2021.04.039_bib37","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.ejca.2017.04.012","article-title":"Factors predictive of locoregional recurrence following neoadjuvant chemotherapy in patients with large operable or locally advanced breast cancer: an analysis of the EORTC 10994\/BIG 1-00 study","volume":"79","author":"Gillon","year":"2017","journal-title":"Eur J Canc"},{"key":"10.1016\/j.ejso.2021.04.039_bib38","doi-asserted-by":"crossref","first-page":"3960","DOI":"10.1200\/JCO.2011.40.8369","article-title":"Predictors of locoregional recurrence after neoadjuvant chemotherapy: results from combined analysis of National Surgical Adjuvant Breast and Bowel Project B-18 and B-27","volume":"32","author":"Mamounas","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2021.04.039_bib39","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1200\/JCO.2002.20.1.17","article-title":"Predictors of loco-regional recurrence after neoadjuvant chemotherapy and mastectomy without radiation","volume":"20","author":"Buchbolz","year":"2002","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.ejso.2021.04.039_bib40","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ijrobp.2003.10.037","article-title":"Pathologic involvement of four or more lymph nodes predict for locoregional recurrence in stage II breast cancer treated with neoadjuvant chemotherapy and mastectomy without radiotherapy","volume":"59","author":"Garg","year":"2004","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ejso.2021.04.039_bib41","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10549-017-4157-0","article-title":"Prognosis of residual axillary disease after neoadjuvant chemotherapy in clinically node-positive breast cancer patients: isolated tumour cells and micrometastases carry a better prognosis than macrometastases","volume":"163","author":"van Nijnatten","year":"2017","journal-title":"Breast Canc Res Treat"},{"key":"10.1016\/j.ejso.2021.04.039_bib42","doi-asserted-by":"crossref","first-page":"100496","DOI":"10.1016\/j.conctc.2019.100496","article-title":"Neonod 2: rationale and design of a multicenter non-inferiority trial to assess the effect of axillary surgery omission on the outcome of breast cancer patients presenting only micrometastasis in the sentinel lymph node after neoadjuvant chemotherapy","volume":"17","author":"Tinterri","year":"2020","journal-title":"ContempClin Trials Commun"}],"container-title":["European Journal of Surgical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798321004716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0748798321004716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:39:33Z","timestamp":1760060373000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0748798321004716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":42,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["S0748798321004716"],"URL":"https:\/\/doi.org\/10.1016\/j.ejso.2021.04.039","relation":{},"ISSN":["0748-7983"],"issn-type":[{"type":"print","value":"0748-7983"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Correlation between outcome and extent of residual disease in the sentinel node after neoadjuvant chemotherapy in clinically fine-needle proven node-positive breast cancer patients","name":"articletitle","label":"Article Title"},{"value":"European Journal of Surgical Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejso.2021.04.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}]}}